Abstract
The protease, human kallikrein-related peptidase 6 (hK6) is derived from activated macrophages in the central nervous system (CNS) and may contribute to pathology observed in multiple sclerosis (MS). In the present study, we compared serum and cerebrospinal fluid (CSF) protein concentrations of human kallikrein-related peptidase 6 derived from neurological controls and patients diagnosed with advanced multiple sclerotic disease. Mean serum levels of human kallikrein-related peptidase 6 were similar in neurological controls and patients diagnosed with relapsing-remitting (RR), secondary progressive (SP) and primary progressive (PP) multiple sclerosis with mean levels ranging from 3.5 to 3.75 ng/ml. Patients diagnosed with advanced multiple sclerosis showed mean CSF levels (29 ng/ml) that were significantly higher than neurological controls (25.5 ng/ml). Determining CSF concentrations of human kallikrein-related peptidase 6 may therefore have diagnostic value in MS.
Keywords: hK6, serum, CSF, RRMS, SPMS, PPMS, human kallikrein-related peptidase 6, central nervous system, cerebrospinal fluid, protease, inflammatory lesions, encephalomyelitis, ELISA, Tetramethylbenzidine, Alzheimer's disease, EDSS
Current Drug Discovery Technologies
Title: Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Volume: 7 Issue: 2
Author(s): Andrea L.O. Hebb, Virender Bhan, Alexander D. Wishart, Craig S. Moore and George S. Robertson
Affiliation:
Keywords: hK6, serum, CSF, RRMS, SPMS, PPMS, human kallikrein-related peptidase 6, central nervous system, cerebrospinal fluid, protease, inflammatory lesions, encephalomyelitis, ELISA, Tetramethylbenzidine, Alzheimer's disease, EDSS
Abstract: The protease, human kallikrein-related peptidase 6 (hK6) is derived from activated macrophages in the central nervous system (CNS) and may contribute to pathology observed in multiple sclerosis (MS). In the present study, we compared serum and cerebrospinal fluid (CSF) protein concentrations of human kallikrein-related peptidase 6 derived from neurological controls and patients diagnosed with advanced multiple sclerotic disease. Mean serum levels of human kallikrein-related peptidase 6 were similar in neurological controls and patients diagnosed with relapsing-remitting (RR), secondary progressive (SP) and primary progressive (PP) multiple sclerosis with mean levels ranging from 3.5 to 3.75 ng/ml. Patients diagnosed with advanced multiple sclerosis showed mean CSF levels (29 ng/ml) that were significantly higher than neurological controls (25.5 ng/ml). Determining CSF concentrations of human kallikrein-related peptidase 6 may therefore have diagnostic value in MS.
Export Options
About this article
Cite this article as:
L.O. Hebb Andrea, Bhan Virender, D. Wishart Alexander, S. Moore Craig and S. Robertson George, Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis, Current Drug Discovery Technologies 2010; 7 (2) . https://dx.doi.org/10.2174/157016310793180611
DOI https://dx.doi.org/10.2174/157016310793180611 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Innate Immunity and Primary Biliary Cirrhosis
Current Molecular Medicine An Evidence-Based Review of Medicinal Plants in the Overall Management of Chronic Fatigue
Current Psychiatry Research and Reviews Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Discretization of Expression Quantitative Trait Loci in Association Analysis Between Genotypes and Expression Data<sup>§</sup>
Current Bioinformatics Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Neural and Behavioral Responses to Systemic Immunologic Stimuli: A Consideration of Bacterial T Cell Superantigens
Current Pharmaceutical Design Cell Surface Markers on Adipose-Derived Stem Cells: A Systematic Review
Current Stem Cell Research & Therapy Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures
Current Topics in Medicinal Chemistry Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib
Current Pharmaceutical Design Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine Inflammatory Events Following Subarachnoid Hemorrhage (SAH)
Current Neuropharmacology The Vitamin D Neuroendocrine System as a Target for Novel Neurotropic Drugs
CNS & Neurological Disorders - Drug Targets CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets Natural Tregs in Systemic Lupus Erythematosus
Current Immunology Reviews (Discontinued) Fatty Acids and Antioxidants in Multiple Sclerosis: Therapeutic Role of GEMSP
Current Pharmaceutical Design Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics
Current Medicinal Chemistry